PRLD
Prelude Therapeutics Incorporated
$3.63
+0.83%
2026-10-23
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Key Fundamentals
Forward P/E
-5.03
EPS (TTM)
$-0.73
ROE
-57.7%
Revenue Growth (YoY)
41.0%
Profit Margin
-269.7%
Debt/Equity
13.20
Price/Book
2.98
Beta
0.96
Market Cap
$308.6M
Avg Volume (10D)
551K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$6.83
60D Low
$3.18
Avg Volume
508K
Latest Close
$3.63
Get breakout alerts for PRLD
Sign up for Breakout Scanner to receive daily notifications when PRLD triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Prelude Therapeutics Incorporated (PRLD) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PRLD daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PRLD operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.